A phase II study of the efficacy, safety, and determinants of response to 5-azacitidine (Vidaza®) in patients with chronic myelomonocytic leukemia

Srinivas K. Tantravahi, Philippe Szankasi, Jamshid S. Khorashad, Kim-Hien Dao, Tibor Kovacsovics, Todd W. Kelley, Michael W. Deininger

Research output: Contribution to journalArticle

6 Scopus citations
Original languageEnglish (US)
Pages (from-to)1-4
Number of pages4
JournalLeukemia and Lymphoma
StateAccepted/In press - Feb 5 2016

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this